Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 24, Issue 6, Pages 573-588Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14728222.2020.1746765
Keywords
Biomarkers; cysteine cathepsins; diagnostics; inflammation-associated diseases; inhibition; theranostics
Categories
Funding
- Slovene Research Agency [P1-0140, N1-0127, J1-1710]
- ICGEB [CRP/SVN 16-01]
Ask authors/readers for more resources
Introduction: Cysteine cathepsins are involved in the development and progression of numerous inflammation-associated diseases such as cancer, arthritis, bone and immune disorders. Consequently, there is a drive to progress research efforts focused on cathepsin use in diagnostics and as therapeutic targets in disease. Areas covered: This review discusses the potential of cysteine cathepsins as therapeutic targets in inflammation-associated diseases and recent advances in preclinical and clinical research. We describe direct targeting of cathepsins for treatment purposes and their indirect use in diagnostics. Expert opinion: The targeting of cysteine cathepsins has not translated into the clinic; this failure is attributed to off- and on-target side effects and/or the lack of companion biomarkers. This field now embraces developments in diagnostic imaging, the activation of prodrugs and antibody-drug conjugates for targeted drug delivery. The future lies in improved molecular tools and therapeutic concepts that will find a wide spectrum of uses in diagnostic and therapeutic applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available